Molecular assay for detection of the common carnitine palmitoyltransferase 1A 1436(C>T) mutation

Jason Y. Park, Srinivas B. Narayan, Michael J. Bennett

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a metabolic disorder that occurs at a key checkpoint of fatty acid metabolism. A new form of CPT1A deficiency caused by a mutation at nucleotide 1436 (C>T), resulting in an amino acid substitution of leucine for proline at position 479 (P479L), has been isolated in Canadian First Nations and Inuit populations. The present study offers a molecular method for assessing CPT1A 1436 (C>T) mutation status. Methods: CPT1A-deficient fibroblasts from four patient fibroblast cell lines and ten patient peripheral blood spots were all analyzed by polymerase chain reaction (PCR) coupled to restriction endonuclease (RE) treatment. Genomic DNA was PCR-amplified and treated with an RE specific for normal DNA. CPT1A 1436 (C>T) mutations were identified by resistance to RE treatment. Results: The RE-PCR assay identified homozygosity for the 1436 (C>T) mutation in four fibroblast cell lines and nine blood spots with CPT1A enzyme deficiency. In addition, the assay identified one blood spot that corresponded to the heterozygous genotype. Conclusions: RE-PCR assay for the 1436 (C>T) mutation provides a rapid assay for the diagnosis of CPT1A deficiency resulting from this mutation. The assay will have utility in screening populations with a high prevalence of this genotype.

Original languageEnglish (US)
Pages (from-to)1090-1091
Number of pages2
JournalClinical Chemistry and Laboratory Medicine
Volume44
Issue number9
DOIs
StatePublished - Sep 1 2006

Fingerprint

Carnitine O-Palmitoyltransferase
Assays
DNA Restriction Enzymes
Polymerase chain reaction
Mutation
Fibroblasts
Polymerase Chain Reaction
Blood
Genotype
Cells
Cell Line
DNA
DNA-Directed DNA Polymerase
Amino Acid Substitution
Proline
Metabolism
Leucine
Population
Screening
Substitution reactions

Keywords

  • 1436 (C>T)
  • Carnitine palmitoyltransferase
  • Carnitine palmitoyltransferase 1A (CPT1A)
  • First Nations
  • Inuit
  • P479L

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Molecular assay for detection of the common carnitine palmitoyltransferase 1A 1436(C>T) mutation. / Park, Jason Y.; Narayan, Srinivas B.; Bennett, Michael J.

In: Clinical Chemistry and Laboratory Medicine, Vol. 44, No. 9, 01.09.2006, p. 1090-1091.

Research output: Contribution to journalArticle

@article{c8841bbd3673422fb4d651a15a045894,
title = "Molecular assay for detection of the common carnitine palmitoyltransferase 1A 1436(C>T) mutation",
abstract = "Background: Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a metabolic disorder that occurs at a key checkpoint of fatty acid metabolism. A new form of CPT1A deficiency caused by a mutation at nucleotide 1436 (C>T), resulting in an amino acid substitution of leucine for proline at position 479 (P479L), has been isolated in Canadian First Nations and Inuit populations. The present study offers a molecular method for assessing CPT1A 1436 (C>T) mutation status. Methods: CPT1A-deficient fibroblasts from four patient fibroblast cell lines and ten patient peripheral blood spots were all analyzed by polymerase chain reaction (PCR) coupled to restriction endonuclease (RE) treatment. Genomic DNA was PCR-amplified and treated with an RE specific for normal DNA. CPT1A 1436 (C>T) mutations were identified by resistance to RE treatment. Results: The RE-PCR assay identified homozygosity for the 1436 (C>T) mutation in four fibroblast cell lines and nine blood spots with CPT1A enzyme deficiency. In addition, the assay identified one blood spot that corresponded to the heterozygous genotype. Conclusions: RE-PCR assay for the 1436 (C>T) mutation provides a rapid assay for the diagnosis of CPT1A deficiency resulting from this mutation. The assay will have utility in screening populations with a high prevalence of this genotype.",
keywords = "1436 (C>T), Carnitine palmitoyltransferase, Carnitine palmitoyltransferase 1A (CPT1A), First Nations, Inuit, P479L",
author = "Park, {Jason Y.} and Narayan, {Srinivas B.} and Bennett, {Michael J.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1515/CCLM.2006.196",
language = "English (US)",
volume = "44",
pages = "1090--1091",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "9",

}

TY - JOUR

T1 - Molecular assay for detection of the common carnitine palmitoyltransferase 1A 1436(C>T) mutation

AU - Park, Jason Y.

AU - Narayan, Srinivas B.

AU - Bennett, Michael J.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Background: Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a metabolic disorder that occurs at a key checkpoint of fatty acid metabolism. A new form of CPT1A deficiency caused by a mutation at nucleotide 1436 (C>T), resulting in an amino acid substitution of leucine for proline at position 479 (P479L), has been isolated in Canadian First Nations and Inuit populations. The present study offers a molecular method for assessing CPT1A 1436 (C>T) mutation status. Methods: CPT1A-deficient fibroblasts from four patient fibroblast cell lines and ten patient peripheral blood spots were all analyzed by polymerase chain reaction (PCR) coupled to restriction endonuclease (RE) treatment. Genomic DNA was PCR-amplified and treated with an RE specific for normal DNA. CPT1A 1436 (C>T) mutations were identified by resistance to RE treatment. Results: The RE-PCR assay identified homozygosity for the 1436 (C>T) mutation in four fibroblast cell lines and nine blood spots with CPT1A enzyme deficiency. In addition, the assay identified one blood spot that corresponded to the heterozygous genotype. Conclusions: RE-PCR assay for the 1436 (C>T) mutation provides a rapid assay for the diagnosis of CPT1A deficiency resulting from this mutation. The assay will have utility in screening populations with a high prevalence of this genotype.

AB - Background: Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a metabolic disorder that occurs at a key checkpoint of fatty acid metabolism. A new form of CPT1A deficiency caused by a mutation at nucleotide 1436 (C>T), resulting in an amino acid substitution of leucine for proline at position 479 (P479L), has been isolated in Canadian First Nations and Inuit populations. The present study offers a molecular method for assessing CPT1A 1436 (C>T) mutation status. Methods: CPT1A-deficient fibroblasts from four patient fibroblast cell lines and ten patient peripheral blood spots were all analyzed by polymerase chain reaction (PCR) coupled to restriction endonuclease (RE) treatment. Genomic DNA was PCR-amplified and treated with an RE specific for normal DNA. CPT1A 1436 (C>T) mutations were identified by resistance to RE treatment. Results: The RE-PCR assay identified homozygosity for the 1436 (C>T) mutation in four fibroblast cell lines and nine blood spots with CPT1A enzyme deficiency. In addition, the assay identified one blood spot that corresponded to the heterozygous genotype. Conclusions: RE-PCR assay for the 1436 (C>T) mutation provides a rapid assay for the diagnosis of CPT1A deficiency resulting from this mutation. The assay will have utility in screening populations with a high prevalence of this genotype.

KW - 1436 (C>T)

KW - Carnitine palmitoyltransferase

KW - Carnitine palmitoyltransferase 1A (CPT1A)

KW - First Nations

KW - Inuit

KW - P479L

UR - http://www.scopus.com/inward/record.url?scp=33748580415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748580415&partnerID=8YFLogxK

U2 - 10.1515/CCLM.2006.196

DO - 10.1515/CCLM.2006.196

M3 - Article

C2 - 16958601

AN - SCOPUS:33748580415

VL - 44

SP - 1090

EP - 1091

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 9

ER -